PL
PLYX
Methodology breakdown computing — it will appear here on its own.
Polaryx Therapeutics, Inc. (PLYX) is currently considered halal (Sharia-compliant), per our secondary compliance provider (last assessed 2026-08-25). See the full ratio breakdown and business-activity screen below for the reasoning.
🕌 In-house Compliance Research
Computing the full ratio and business-activity breakdown for PLYX — this runs off the critical path so the page paints first. It will appear here on its own.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
Price Forecast
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally above. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
Technical Summary
Every indicator, and what it reads
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 44.60 | NEUTRAL |
| Stochastic %K (14) | 48.39 | NEUTRAL |
| CCI (20) | -56.53 | NEUTRAL |
| Williams %R (14) | -51.61 | NEUTRAL |
| MACD (12,26,9) | 0.01 | BUY |
| ROC (10) | -5.21 | SELL |
| Momentum (10) | -0.11 | SELL |
| EMA (10) | 2.03 | SELL |
| SMA (10) | 2.02 | BUY |
| EMA (20) | 2.07 | SELL |
| SMA (20) | 2.07 | SELL |
| EMA (30) | 2.12 | SELL |
| SMA (30) | 2.13 | SELL |
| EMA (50) | 2.29 | SELL |
| SMA (50) | 2.19 | SELL |
| EMA (100) | 3.14 | SELL |
| SMA (100) | 2.75 | SELL |
| EMA (200) | 4.03 | SELL |
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
About Polaryx Therapeutics, Inc.
Healthcare · Biotechnology
Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, a preclinical stage novel gene therapy candidate. The company was founded in 2014 and is based in Paramus, New Jersey.
Background via Yahoo Finance — informational, not part of the verdict.
⚪ NEUTRAL — No Edge
Signals are mixed with no clear edge in either direction. Stand aside and wait for one more confluence factor.
Scores: 2 bullish / 1 bearish
Weak — low conviction, small size or skip
SMC — Top Down
| Timeframe | Bias | Bars |
|---|---|---|
| 📅 Daily | BULLISH | 61 |
| ⏰ 4H | BEARISH | 19 |
| 🕐 1H | BEARISH | 76 |
| ⏱ 15-Min | BULLISH | 130 |
| ⏲ 5-Min | BEARISH | 234 |
Momentum & Volume
Peer Movement
Peer movement computing — it will appear here on its own.
Insider Activity (90d)
NO DATA 0 buys · 0 sells
COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE
NEUTRAL report date 2026-09-01 · Asset managers net 934180 (-19048)
AI Summary
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.